###begin article-title 0
###xml 45 50 45 50 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">trans</italic>
###xml 0 18 <span type="species:ncbi:10376">Epstein-Barr virus</span>
Epstein-Barr virus latent membrane protein 1 trans-activates miR-155 transcription through the NF-kappaB pathway
###end article-title 0
###begin p 1
Present address: Sven Kroening, Universitatsklinikum Erlangen, Medizinische Klinik 4, Erlagen, DE, Germany
###end p 1
###begin p 2
The authors wish it to be known that, in their opinion, the first two authors should be regarded as joint First Authors
###end p 2
###begin p 3
###xml 0 16 0 16 <!--CREATIVE COMMONS-->
CREATIVE COMMONSThis is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License () which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 3
###begin p 4
###xml 172 173 172 173 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">'</bold>
###xml 4 22 <span type="species:ncbi:10376">Epstein-Barr virus</span>
###xml 24 27 <span type="species:ncbi:10376">EBV</span>
###xml 169 172 <span type="species:ncbi:10376">EBV</span>
###xml 411 414 <span type="species:ncbi:10376">EBV</span>
###xml 444 447 <span type="species:ncbi:10376">EBV</span>
###xml 546 549 <span type="species:ncbi:10376">EBV</span>
###xml 706 709 <span type="species:ncbi:10376">EBV</span>
###xml 767 770 <span type="species:ncbi:10376">EBV</span>
###xml 1309 1312 <span type="species:ncbi:10376">EBV</span>
The Epstein-Barr virus (EBV)-encoded latent membrane protein-1 (LMP1), a functional homologue of the tumor necrosis factor receptor family, substantially contributes to EBV's oncogenic potential by activating nuclear factor-kappaB (NF-kappaB). miR-155 is an oncogenic miRNA critical for B-cell maturation and immunoglobulin production in response to antigen. We report that miR-155 expression is much higher in EBV-immortalized B cells than in EBV-negative B cells. LMP1, but not LMP2, up-regulated the expression of miR-155, when transfected in EBV-negative B cells. We analyzed two putative NF-kappaB binding sites in the miR-155 promoter; both sites recruited NF-kappaB complex, in nuclear extract from EBV-immortalized cells. The exogenous expression of LMP1, in EBV-negative background, is temporally correlated to induction of p65 with binding on both NF-kappaB sites and with miR-155 overexpression. The induction of p65 binding together with increased RNA polymerase II binding, confirms that LMP1-mediated activation of miR-155 occurs transcriptionally. In reporter assays, miR-155 promoter lacking NF-kappaB binding sites was no longer activated by LMP1 expression and an intact AP1 site is needed to attain maximum activation. Finally, we demonstrate that LMP1-mediated activation of miR-155 in an EBV-negative background correlates with reduction of protein PU.1, which is a possible miR target.
###end p 4
###begin title 5
INTRODUCTION
###end title 5
###begin p 6
###xml 409 410 409 410 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B1">1</xref>
###xml 411 412 411 412 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B2">2</xref>
###xml 727 728 727 728 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B2">2</xref>
###xml 855 856 855 856 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B3">3</xref>
###xml 857 858 857 858 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B4">4</xref>
###xml 975 983 975 983 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 1177 1178 1177 1178 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B3">3</xref>
###xml 0 18 <span type="species:ncbi:10376">Epstein-Barr virus</span>
###xml 20 23 <span type="species:ncbi:10376">EBV</span>
###xml 208 211 <span type="species:ncbi:10376">EBV</span>
###xml 415 418 <span type="species:ncbi:10376">EBV</span>
###xml 651 654 <span type="species:ncbi:10376">EBV</span>
###xml 778 781 <span type="species:ncbi:10376">EBV</span>
###xml 932 935 <span type="species:ncbi:10376">EBV</span>
###xml 1032 1047 <span type="species:ncbi:10090">transgenic mice</span>
###xml 1171 1175 <span type="species:ncbi:10090">mice</span>
Epstein-Barr virus (EBV), which infects over 90% of the adults, appears to have evolved to exploit the normal biology of B-cell development in order to persist as a life-long asymptomatic infection. However, EBV can contribute to oncogenesis. Indeed, it is frequently found in Burkitt's lymphoma, Hodgkin's lymphoma, nasopharyngeal carcinoma and lymphoproliferative diseases in immune-suppressed individuals (1,2). EBV-related oncogenesis is principally associated with latency during which only a limited subset of the full repertoire of viral genes are transcribed. In addition to protein-coding genes, the non-coding RNAs EBER1, EBER2 and a set of EBV-encoded microRNAs (miRNAs) are expressed in all three forms of latency (2). Of the genes expressed during viral latency in EBV-associated diseases, LMP1 is the one most implicated in tumor formation (3,4). LMP1 is invariably expressed in Burkitt's lymphoma, it is required for EBV-mediated transformation of lymphocytes in vitro and it transforms rodent fibroblasts. Moreover, transgenic mice expressing LMP1 under the control of an immunoglobulin promoter develop B lymphocyte tumors more frequently than wild-type mice (3).
###end p 6
###begin p 7
###xml 262 265 262 265 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B5 B6 B7 B8">5&#8211;8</xref>
###xml 410 414 410 414 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B9 B10 B11 B12">9&#8211;12</xref>
###xml 710 714 702 706 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B8 B9 B10 B11 B12">8&#8211;12</xref>
LMP1 is a six-transmembrane constitutively active signaling molecule that functionally mimics members of the cellular tumor necrosis factor receptor (TNFR) family. While the transmembrane domains are required for aggregation and constitutive activation of LMP1 (5-8), two cytoplasmic domains, i.e. the C-terminal activator regions 1 and 2 (CTAR-1 and -2), are critical for the transforming properties of LMP1 (9-12). Together, these signaling domains act through cellular TNFR-associated factors (TRAFs) and other cell-signaling molecules to activate, three transcription factors, namely, nuclear factor-kappaB (NF-kappaB), activator transcription factor-2 (ATF)-2 and AP-1, via c-Jun N-terminal kinase (JNK) (8-12). By manipulating these cell-signaling pathways, LMP1 affects host cellular processes that regulate cell proliferation, migration and apoptosis, thereby contributing to cellular immortalization and tumorigenesis.
###end p 7
###begin p 8
###xml 219 221 219 221 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B13">13</xref>
###xml 350 352 350 352 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B14">14</xref>
###xml 490 495 490 495 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B14 B15 B16 B17 B18 B19">14&#8211;19</xref>
###xml 616 623 616 623 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 625 627 625 627 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B20">20</xref>
###xml 628 630 628 630 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B21">21</xref>
###xml 810 812 803 805 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B16">16</xref>
###xml 813 815 806 808 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B22">22</xref>
###xml 235 240 <span type="species:ncbi:10090">mouse</span>
###xml 1077 1080 <span type="species:ncbi:10376">EBV</span>
The miR-155 is processed from a primary transcript, known as 'BIC' (B-cell integration cluster), whose upstream region was originally found to be a frequent site of integration of the avian leucosis virus in lymphomas (13). Transgenic mouse studies demonstrated that B-cell targeted expression of BIC leads to the development of B-cell malignancies (14). Furthermore, a number of miRNA profiling studies have shown elevated levels of miR-155 in a wide array of cancers including lymphomas (14-19). miR-155 is one of the miRNAs most frequently implicated in cancers. It plays a critical role in lymphocyte activation in vivo (20,21) and is induced by a variety of immune cell stimuli, i.e. toll-like receptor (TLR) ligands, TNF-alpha, interferon-beta (IFN-beta) and antigens [B-cell receptor (BCR) engagement] (16,22). The mechanism by which miR-155 is regulated after TLR and IFN signaling in macrophages is still unknown. Here we show that LMP1 upregulates the expression of miR-155 mainly by activating the NF-kappaB pathway, which suggests that miR-155 can cooperate in the EBV-mediated transformation of B cells.
###end p 8
###begin title 9
MATERIALS AND METHODS
###end title 9
###begin title 10
Cell culture
###end title 10
###begin p 11
###xml 0 3 <span type="species:ncbi:10376">EBV</span>
###xml 13 18 <span type="species:ncbi:9606">human</span>
###xml 39 42 <span type="species:ncbi:10376">EBV</span>
###xml 56 61 <span type="species:ncbi:9606">human</span>
###xml 341 347 <span type="species:ncbi:9913">bovine</span>
###xml 387 393 <span type="species:ncbi:10090">Murine</span>
###xml 611 617 <span type="species:ncbi:9913">bovine</span>
EBV-negative human B cells (DeFew) and EBV-immortalized human B cells MC3 (kindly provided by Prof. Giuseppe Scala, University 'Magna Grecia' Catanzaro) Devozione, Cap (kindly provided by Dr Giuseppina Ruggiero, University 'Federico II', Naples), were cultured in RPMI 1640 medium (Invitrogen, Carlsbad, CA, USA) supplemented with 10% fetal bovine serum (Invitrogen) and 2 mM glutamine. Murine embryonic fibroblasts (MEFs) and HEK 293 referred to as LinX, stably transfected with the helper vector, [LinX cell line, Openbiosystem, ()] were cultured in DMEM medium (GIBCO-Invitrogen) supplemented with 10% fetal bovine serum (Invitrogen) and 2 mM glutamine.
###end p 11
###begin title 12
RNA preparation and northern blot
###end title 12
###begin p 13
###xml 420 423 413 416 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">bis</italic>
###xml 692 693 685 686 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1082 1083 1068 1069 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 1100 1102 1082 1084 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">32</sup>
###xml 940 946 <span type="species:ncbi:9913">bovine</span>
Total RNA was extracted using Trizol reagent (Invitrogen) according to supplier's protocol. Northern blot analysis was carried out on 15 mug of total RNAs. Briefly, all RNA samples were dissolved in loading buffer [0.05% bromophenol blue, 0.05% cyanol, 5% Ficoll (type 400), 80% formamide and 7 M urea], boiled for 5 min at 95degreesC and loaded onto 15% polyacrylamide gel under denaturizing conditions [15% acrylamide-bis-acrylamide 19/1, 45 mM Tris, 45 mM boric acid, 1 mM EDTA pH 8, 7 M urea, 0.01% N,N,N',N'-tetramethylethylenediamine (TEMED) and 0.1% ammonium persulfate (APS)]. Samples were resolved by electrophoresis for 90 min at 150 V and transferred onto nylon membranes (Hybond N+, Amersham/GE Healthcare, Little Chalfont, UK) by capillary blot. The nylon membranes were then equilibrated in 1 M NaCl and pre-hybridized in 6x SSC, 5x Denhart's solution (1x Denhart's solution = 0.1% Ficoll, 0.1% polyvinyl pyrrolydone and 0.1% bovine serum albumin), 5 mug/ml of sheared salmon sperm ds-DNA (Ambion, Austin TX, USA) at 42degreesC for 2 h. After pre-hybridization, 1 x 106 CPM/ml of [gamma32P-ATP] radiolabeled oligonucleotide probe was added and the hybridization carried out overnight at 42degreesC. The membranes were washed twice in 2x SSC, 1% SDS at 42degreesC for 30 min and exposed either by autoradiography or by phosphorimage screen (Amersham/GE Healthcare). The signals were quantified with image-scanning or by Image-J software analysis.
###end p 13
###begin title 14
Western blot analysis
###end title 14
###begin p 15
###xml 328 330 321 323 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B23">23</xref>
###xml 406 409 399 402 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">bis</italic>
###xml 507 510 500 503 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">bis</italic>
###xml 985 990 <span type="species:ncbi:10090">mouse</span>
###xml 1076 1081 <span type="species:ncbi:10090">mouse</span>
###xml 1136 1142 <span type="species:ncbi:9986">rabbit</span>
###xml 1197 1203 <span type="species:ncbi:9986">rabbit</span>
###xml 1241 1247 <span type="species:ncbi:9986">rabbit</span>
###xml 1351 1356 <span type="species:ncbi:9796">horse</span>
###xml 1357 1363 <span type="species:ncbi:3726">radish</span>
The cell pellets were resuspended in 1 ml of lysis buffer [10 mM HEPES, pH 7.4, 150 mM KCl, 1 mM EDTA pH 8, 1% Triton X-100, 1 mM DTT, 1 mM orthovadanate, 1 mM NaF and protease inhibitor cocktail (Roche, Basel, Switzerland)] at 4degreesC for 20 min. Then, 40 mug of proteins, of each sample, were resuspended in Laemmli buffer (23) and resolved by SDS-PAGE (running gel: 0.4 M Tris, pH 8.8, 12% acrylamide/bis-acrylamide 37/1, 0.1% SDS, 0.01% TEMED, 0.1% APS; staking gel: 0.07 M Tris pH 6.8, 5% acrylamide/bis-acrylamide 37/1, 0.1% SDS, 0.01% TEMED, 0.1% APS). The proteins were transferred onto nitrocellulose membranes (Hybond ECL, Amesham/GE Healthcare) by electroblotting. Membranes were blocked in 5% of 'non-fat milk' (BioRad, Hercules CA, USA) 0.5% BSA in phosphate buffer solution for 2 h at room temperature and immunoblotted with monoclonal antibody against LMP1 (kindly provided by Dr Dong Yun Lee, McArdle Laboratory for Cancer Research, University of Wisconsin-Madison), mouse polyclonal antibody against gamma-tubulin (Sigma Chemical Company, St Louis MO, USA) mouse monoclonal antibody against p65 (SantaCruz, CA, USA), rabbit polyclonal antibody against IkappaBalpha (SantaCruz), rabbit polyclonal against H3 (SantaCruz) or rabbit polyclonal antibody against PU.1 (Santa Cruz). Specific secondary antibodies (Sigma Chemical Company), horse-radish peroxidase conjugated, were used for protein detection by enhanced chemiluminescence (ECL, Amesham/GE Healthcare) followed by autoradiography (Hyperfilm ECL, Amesham/GE Healthcare). We used the Image-J software for densitometric analysis.
###end p 15
###begin title 16
Cloning and mutagenesis of BIC/miR-155 promoter
###end title 16
###begin p 17
###xml 4 9 <span type="species:ncbi:9606">human</span>
The human BIC/miR-155 promoter region extending from 1783 to 1, from 1380 to 1, from 1065 to 1 relative to the start site was isolated from MC3 genomic DNA by PCR using the following primers:
###end p 17
###begin p 18
Fw AGCTGAGCTCGAAAGGTCACCCTAGAATTG (-1783),
###end p 18
###begin p 19
Fw AGCTGAGCTCGATCTGGCACATGGTAAATG (-1380),
###end p 19
###begin p 20
Fw AGCTGAGCTCCAGTCACATGTTGATGAGGC (-1065),
###end p 20
###begin p 21
Rev CATGAAGCTTATCCGCTCCCTTCCCGAG (+1).
###end p 21
###begin p 22
The isolated fragments were digested with SacI and HindIII and cloned into SacI and HindIII cut pGL3basic (Promega, Madison, WI, USA). The entire promoter region was sequenced and no discrepancies were identified relative to the Genebank genomic sequence ().
###end p 22
###begin p 23
Mutagenesis of the pLuc1380 and pLuc1783 reporter plasmid was carried out with the 'Expand Long Template PCR system' (Roche) and the following oligonucleotides: 5'-GTA AAT TAA GTA CTA TGC TCG AGC CAG CTC TGA CAT G-3' and 5'-CAT AGT ACT TAA TTT ACA GAT GGC TCA GGT TGG TTA AG-3' (NF-kB1), Fw 5'-CAACCTAGAATGAGAAATGCTCGAGTCAGAAAGGCATTGTAGG-3' and Rev 5'-CATTTCTCATTCTAGGTTGAACTATACCTCCCTTCTCCCAGTG-3' (NF-kappaB2), 5'-GGC GCC TGG TCG GTT ATC TCG AGC AAG TGA GTT ATA AAA-3' and 5'-ATA ACC GAC CAG GCG CCT TTT CTG CAA CCC-3' (AP-1). In each case, the core transcription factor binding site was replaced by a XhoI restriction site. Mutations were initially screened by digesting with XhoI and then verified by sequence analysis.
###end p 23
###begin title 24
Reporter analysis
###end title 24
###begin p 25
###xml 33 34 33 34 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 562 563 549 550 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
For each reporter plasmid, 2 x 106 MEFs were distributed in 6 cm dish plates containing 5 ml RPMI1640 (Invitrogen) 10% FBS (Cambrex, East Rutherford, NJ, USA), 2 mM glutamine. FuGene (Roche) of 6 mul were added to 300 mul of DMEM and incubated for 5 min at room temperature. Each reporter vector of 0.5 mug plus 0.2 mug of beta-galactosidase vector were then added to the mixture, the tubes were shacked and incubated at room temperature for 15 min. For each transfection, the mixtures were then added to each plate and plates were incubated at 37degreesC, 5% CO2 for 48 h. Cells were harvested 48 h later and assayed for luciferase activity. Results are presented as average of three independent experiments.
###end p 25
###begin p 26
###xml 33 34 33 34 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 535 536 522 523 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
For each reporter plasmid, 2 x 106 DeFew were distributed in 6 cm dish plates containing 5 ml RPMI1640 (Invitrogen) 10% FBS (Cambrex), 4 mM glutamine. FuGene (Roche) of 8 mul were added to 300 mul of DMEM and incubated for 5 min at room temperature. Each reporter vector of 1 mug plus 0.5 mug of beta-galactosidase vector were then added to the mixture, the tubes were shacked and incubated at room temperature for 15 min. For each transfection, the mixtures were then added to each plate and plates were incubated at 37degreesC, 5% CO2. After 6 h each sample was split in two, and one of them was treated with 10 ng/ml of phorbol myristoylated acetate (PMA). Cells were harvested 48 h later and assayed for luciferase activity. Results are presented as average of three independent experiments.
###end p 26
###begin title 27
Chromatin immunoprecipitation assay
###end title 27
###begin p 28
###xml 26 27 26 27 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 704 708 <span type="species:ncbi:4530">Rice</span>
MC3 or DeFew cells (5 x 106 cells) were exposed to 1% formaldehyde for 10 min at 37degreesC to obtain protein-DNA cross-linking. The nuclear fraction was sonicated to yield chromatin fragments of 200-1000 bp; 5% of the total volume was removed from each sample and used as the input fraction. Chromatin was pre-cleared by pre-incubation with a DNA salmon sperm/protein A-agarose 50% slurry (Upstate, Temecula, CA, USA) for 1 h at 4degreesC. The agarose was centrifuged, and the pre-cleared chromatin supernatant was incubated with the antibodies (3 mug) against RNA pol II (mAb anti RNA polymerase II, Active Motif, Rixensart, Belgium), p50 or p65 (pAb anti p50 or pAb anti p65, kindly provided by Dr N. Rice, Frederick Cancer Research and Development Center, Frederick, MD, USA), against histone 3 (pAb anti H3, SantaCruz), overnight at 4degreesC. The protein-DNA-antibody complexes were collected by the addition of the salmon sperm DNA-protein A-agarose (2 h at 4degreesC) and washed, and protein-DNA cross-linking was reversed (4 h at 65degreesC). DNA was purified by phenol/chloroform extraction and ethanol precipitation and aliquots (25%) of the purified materials underwent PCR (5 min at 94degreesC, 1 min at 94degreesC, 1 min at 52degreesC, 1 min at 72degreesC for 40 cycles, 5 min at 72degreesC).
###end p 28
###begin title 29
Preparation of nuclear extracts and electrophoresis mobility shift assay
###end title 29
###begin p 30
###xml 23 24 23 24 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 202 203 202 203 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 523 524 509 510 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 944 951 900 903 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#947;32</sup>
###xml 970 972 922 924 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8211;1</sup>
MC3 cells (5- to 6 x 106 cells) were washed with cold phosphate buffered saline and harvested. The cell pellet was resuspended in extraction buffer containing 10 mM HEPES, pH 7.9, 10 mM KCl, 1.5 mM MgCl2, 0.1 mM EGTA, 0.5 mM DTT, 0.5 mM PMSF, 10 microg/ml aprotinin, 10 microg/ml leupeptin, passed through a needle, kept on ice for 45 min, and centrifuged (15 min at 14 000 r.p.m. at 4degreesC). The nuclear pellet was then resuspended in high salt extraction buffer containing 10 mM HEPES, pH 7.9, 0.4 mM NaCl, 1.5 mM MgCl2, 0.1 mM EGTA, 0.5 mM DTT, 0.5 mM phenylmethylsulfonyl fluoride, 10 microg/ml aprotinin, 10 microg/ml leupeptin and incubated for 45 min at 4degreesC. The nuclear extract supernatant was obtained by centrifugation (30 min at 14 000 r.p.m. at 4degreesC), protein concentration was determined and 5 microg aliquots were stored at -80degreesC until used. Double-stranded synthetic oligonucleotides were radiolabeled using [gamma32P]ATP (3000 Ci mmol-1; Amersham Biosciences) and T4 polynucleotide kinase (Fermentas, Burlington, ON, Canada). The binding reaction was carried out for 20 min at room temperature with 5 microg of nuclear proteins in 10% glycerol, 60 mM KC1, 1 mM EDTA, 1 mM dithiothreitol and 0.250 microg/microl poly[dI-dC] containing 50 000 cpm of radiolabeled probe and a 80-fold molar excess of unlabeled competitor oligonucleotide when indicated. For supershift experiments, 4 microg of specific anti-p65 or anti-p50 were added to the binding reaction and incubated for 30 min, after which we added the radiolabeled probe. DNA-protein complexes were separated by 5% non-denaturing polyacrylamide gel and revealed by either autoradiography or phosphorimage screen (Amersham Biosciences).
###end p 30
###begin title 31
Transient transfection
###end title 31
###begin p 32
###xml 19 20 19 20 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
DeFew cells (3 x 106 cells) were centrifuged, washed in PBS and resuspended in 300 mul of electroporation medium (RPMI 1640 medium, 20% FBS and 2 mM Glutamine). Cells were mixed with 20 mug of plasmid expressing LMP1 (pcDNA3-LMP1), or LMP2 (pcDNA3-LMP2) or both and subsequently transferred in electroporation cuvette. Cells were electroporated twice at 220 V, 960 muFa and incubated 5 min on ice. Cells were plated in 10 ml of RPMI 1640 medium, 10% FBS and 2 mM glutamine for 2 days. After 2 days, they were harvested and assayed for miR-155 and LMP1 expression.
###end p 32
###begin title 33
Viral generation, infection and time course
###end title 33
###begin p 34
###xml 366 367 365 366 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
The retroviral vector LMP1pBABE-puro was kindly provided by Prof. Eiji Hara (University of Tokushima, Japan). LinX cell line, stably transfected with the helper vector, were grown in DMEM medium 10% FBS, 2 mM glutamine and 100 mug/ml hygromicin. Transfections with LMP1pBABEpuro or pBABEpuro (empty vector) were as follows: 6 cm plate of semi-confluent (about 1 x 106 cells) cells were transfected and 7.5 mug of DNA vector incubated in 20 mul of FuGene and incubated in 4 ml of medium without antibiotic for 24 h. After incubation, the medium was harvested, replaced with 4 ml of fresh medium and the LinX cells incubated for 24 h for a second round of viral generation.
###end p 34
###begin p 35
###xml 19 20 19 20 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 359 360 346 347 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
DeFew cells (4 x 106 cells) were centrifuged, washed in PBS and resuspended in 4 ml of virus containing medium plus 4 mug/ml of Polybrene (Sigma). The infection was performed by spinoculation, namely by centrifugation at 3500 r.p.m. for 90 min at 20degreesC. After centrifugation, the cells were resuspended in 10 ml of RPMI and incubated at 37degreesC, 5% CO2. Twenty-four hours later, the cells underwent a second round of infection. After 48 h, cells were treated with 1 mug/ml of puromicine to start selection of positive clones.
###end p 35
###begin p 36
###xml 40 41 40 41 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 382 383 369 370 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
For the time course, DeFew cells (4 x 106 cells) were centrifuged, washed in PBS and resuspended in 12 ml of virus containing medium plus 12 mug/ml of Polybrene (Sigma). The infection was performed by spinoculation, namely by centrifugation at 3500 r.p.m. for 90 min at 20degreesC. After centrifugation, the cells were resuspended in 10 ml of RPMI and incubated at 37degreesC, 5% CO2. Twenty-four hours later, 1 mug/ml of puromocine was added to cells to start selection. Cells were harvested at 6, 24, 48 and 72 h after infection and assayed for miR-155 and LMP1 expression.
###end p 36
###begin title 37
Transient transfection of MC3
###end title 37
###begin p 38
###xml 17 18 17 18 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 205 208 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
MC3 cells (3 x 106 cells) were centrifuged, washed in PBS and resuspended in 300 mul of electroporation medium (RPMI 1640 medium, 20% FBS and 2 mM glutamine). Cells were mixed in a tube with 20 mug of pRc/CMV-HA-IkappaBalpha-S32/36A (kindly provided by Prof. Ileana Quinto, University Magna Grecia, Catanzaro) and subsequently put in electroporation cuvette. Cells were electroporated twice at 220 V, 960 muFa and incubated 5 min on ice. Cells were plated in 10 ml of RPMI 1640 medium, 10% FBS and 4 mM glutamine for 2 days. After 2 days, they were harvested and assayed for miR-155, p65 and IkappaBalpha expression.
###end p 38
###begin title 39
RESULTS
###end title 39
###begin title 40
The expression of mir-155 is regulated by LMP1
###end title 40
###begin p 41
###xml 240 248 240 248 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">Figure 1</xref>
###xml 342 348 342 348 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al.</italic>
###xml 350 352 350 352 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B24">24</xref>
###xml 480 488 480 488 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">Figure 1</xref>
###xml 620 622 620 622 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B25">25</xref>
###xml 656 658 656 658 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B26">26</xref>
###xml 661 670 661 670 <label xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 1.</label>
###xml 670 1019 670 1019 <p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" textid="42">miR-155 is upregulated in EBV-immortalized cell lines. Northern blot analysis on total RNAs obtained from 9 cell lines. The blot was analyzed for the expression of mature miR-155 and normalized by the ubiquitous small nuclear RNA U6. Note that basal levels of miR-155 expression in DeFew cells are not visible in this blot due to the brief exposure.</p>
###xml 670 1019 670 1019 <caption xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><p textid="42">miR-155 is upregulated in EBV-immortalized cell lines. Northern blot analysis on total RNAs obtained from 9 cell lines. The blot was analyzed for the expression of mature miR-155 and normalized by the ubiquitous small nuclear RNA U6. Note that basal levels of miR-155 expression in DeFew cells are not visible in this blot due to the brief exposure.</p></caption>
###xml 1019 1019 1019 1019 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xlink:href="gkn666f1"/>
###xml 661 1019 661 1019 <fig xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="F1" position="float"><label>Figure 1.</label><caption><p textid="42">miR-155 is upregulated in EBV-immortalized cell lines. Northern blot analysis on total RNAs obtained from 9 cell lines. The blot was analyzed for the expression of mature miR-155 and normalized by the ubiquitous small nuclear RNA U6. Note that basal levels of miR-155 expression in DeFew cells are not visible in this blot due to the brief exposure.</p></caption><graphic xlink:href="gkn666f1"/></fig>
###xml 40 43 <span type="species:ncbi:10376">EBV</span>
###xml 104 107 <span type="species:ncbi:10376">EBV</span>
###xml 303 306 <span type="species:ncbi:10376">EBV</span>
###xml 362 365 <span type="species:ncbi:10376">EBV</span>
###xml 450 453 <span type="species:ncbi:10376">EBV</span>
###xml 592 597 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 696 699 <span type="species:ncbi:10376">EBV</span>
We measured miR-155 expression in three EBV-immortalized cell lines (MC3, Devozione and Cap) and in two EBV-negative B-cell lines (EW36 and DeFew), a T-cell lymphoma cell line (Jurkat) and NB4 from acute promyelocytic leukemia. As shown in Figure 1, miR-155 was expressed at relevant levels only in the EBV-positive cells according to Mrazek et al. (24). In the EBV-negative B cells, miR-155 expression was not affected by stable transfection of the EBV nuclear factor 2 (EBNA2) (Figure 1), a viral transacting factor that activates the expression of such cellular and viral promoters as the HIV-1 long terminal repeat (25) and the interleukin-6 promoter (26). Figure 1.miR-155 is upregulated in EBV-immortalized cell lines. Northern blot analysis on total RNAs obtained from 9 cell lines. The blot was analyzed for the expression of mature miR-155 and normalized by the ubiquitous small nuclear RNA U6. Note that basal levels of miR-155 expression in DeFew cells are not visible in this blot due to the brief exposure.
###end p 41
###begin p 42
###xml 26 29 <span type="species:ncbi:10376">EBV</span>
miR-155 is upregulated in EBV-immortalized cell lines. Northern blot analysis on total RNAs obtained from 9 cell lines. The blot was analyzed for the expression of mature miR-155 and normalized by the ubiquitous small nuclear RNA U6. Note that basal levels of miR-155 expression in DeFew cells are not visible in this blot due to the brief exposure.
###end p 42
###begin p 43
###xml 339 347 339 347 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F2">Figure 2</xref>
###xml 563 571 563 571 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F2">Figure 2</xref>
###xml 699 707 699 707 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F2">Figure 2</xref>
###xml 890 898 890 898 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F2">Figure 2</xref>
###xml 908 917 908 917 <label xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 2.</label>
###xml 990 991 990 991 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 1243 1244 1243 1244 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 1344 1345 1344 1345 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</bold>
###xml 1530 1531 1526 1527 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">D</bold>
###xml 1757 1758 1753 1754 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E</bold>
###xml 1858 1859 1854 1855 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">F</bold>
###xml 917 2025 917 2017 <p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" textid="44">LMP1 enhances the expression of miR-155 in an EBV-negative B-cell line. (<bold>A</bold>) A representative northern blot analysis on total RNAs obtained from DeFew cells transfected (TF) as indicated or untransfected (UT). The blot was analyzed for the expression of mature miR-155 and normalized by the ubiquitous small nuclear RNA (U6). (<bold>B</bold>) Graphic representation of the northern blot results as average of three independent experiments. (<bold>C</bold>) Western blot analysis of LMP1 expression in the transfected cells compared to MC3 cell immortalized by EBV. Input proteins were equalized by detecting the endogeneous &#947;-tubulin. (<bold>D</bold>) Northern blot analysis of total RNAs obtained from DeFew cells at 72 h post-infection with retroviral vector expressing LMP1 or empty vector. The blot was analyzed for the expression of mature miR-155 and normalized by U6. (<bold>E</bold>) Graphic representation of the northern blot results as average of three independent experiments. (<bold>F</bold>) Western blot analysis of the expression of LMP1 upon infection with the retroviral vector. Input proteins were equalized by detecting the endogeneous &#947;-tubulin.</p>
###xml 917 2025 917 2017 <caption xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><p textid="44">LMP1 enhances the expression of miR-155 in an EBV-negative B-cell line. (<bold>A</bold>) A representative northern blot analysis on total RNAs obtained from DeFew cells transfected (TF) as indicated or untransfected (UT). The blot was analyzed for the expression of mature miR-155 and normalized by the ubiquitous small nuclear RNA (U6). (<bold>B</bold>) Graphic representation of the northern blot results as average of three independent experiments. (<bold>C</bold>) Western blot analysis of LMP1 expression in the transfected cells compared to MC3 cell immortalized by EBV. Input proteins were equalized by detecting the endogeneous &#947;-tubulin. (<bold>D</bold>) Northern blot analysis of total RNAs obtained from DeFew cells at 72 h post-infection with retroviral vector expressing LMP1 or empty vector. The blot was analyzed for the expression of mature miR-155 and normalized by U6. (<bold>E</bold>) Graphic representation of the northern blot results as average of three independent experiments. (<bold>F</bold>) Western blot analysis of the expression of LMP1 upon infection with the retroviral vector. Input proteins were equalized by detecting the endogeneous &#947;-tubulin.</p></caption>
###xml 2025 2025 2017 2017 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xlink:href="gkn666f2"/>
###xml 908 2025 908 2017 <fig xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="F2" position="float"><label>Figure 2.</label><caption><p textid="44">LMP1 enhances the expression of miR-155 in an EBV-negative B-cell line. (<bold>A</bold>) A representative northern blot analysis on total RNAs obtained from DeFew cells transfected (TF) as indicated or untransfected (UT). The blot was analyzed for the expression of mature miR-155 and normalized by the ubiquitous small nuclear RNA (U6). (<bold>B</bold>) Graphic representation of the northern blot results as average of three independent experiments. (<bold>C</bold>) Western blot analysis of LMP1 expression in the transfected cells compared to MC3 cell immortalized by EBV. Input proteins were equalized by detecting the endogeneous &#947;-tubulin. (<bold>D</bold>) Northern blot analysis of total RNAs obtained from DeFew cells at 72 h post-infection with retroviral vector expressing LMP1 or empty vector. The blot was analyzed for the expression of mature miR-155 and normalized by U6. (<bold>E</bold>) Graphic representation of the northern blot results as average of three independent experiments. (<bold>F</bold>) Western blot analysis of the expression of LMP1 upon infection with the retroviral vector. Input proteins were equalized by detecting the endogeneous &#947;-tubulin.</p></caption><graphic xlink:href="gkn666f2"/></fig>
###xml 963 966 <span type="species:ncbi:10376">EBV</span>
###xml 1450 1453 <span type="species:ncbi:10376">EBV</span>
To evaluate whether LMP1 induces miR activation, we transiently transfected a vector expressing LMP1, LMP2 or both in DeFew cells (EVB-negative B cells). There was a 1.6-fold induction of miR-155 expression in LMP1-transfected cells, no induction in LMP2-transfected cells and a 1.7-fold induction in cells transfected with LMP1 and LMP2 (Figure 2A and B). The significance of this finding is underestimated because only a few cells were transfected by LMP1 expression vector. Indeed, LMP1 was much lower in transiently transfected DeFew cells than in MC3 cells (Figure 2C). To overcome this problem, we infected the DeFew cells with a retroviral vector expressing LMP1 (pBABEpuroLMP1). As shown in Figure 2D, we obtained a higher expression of LMP1, at 72 h post-infection, resulting in about 3.5-fold induction of miR-155 expression compared to DeFew cells infected with the empty virus (Figure 2E and F). Figure 2.LMP1 enhances the expression of miR-155 in an EBV-negative B-cell line. (A) A representative northern blot analysis on total RNAs obtained from DeFew cells transfected (TF) as indicated or untransfected (UT). The blot was analyzed for the expression of mature miR-155 and normalized by the ubiquitous small nuclear RNA (U6). (B) Graphic representation of the northern blot results as average of three independent experiments. (C) Western blot analysis of LMP1 expression in the transfected cells compared to MC3 cell immortalized by EBV. Input proteins were equalized by detecting the endogeneous gamma-tubulin. (D) Northern blot analysis of total RNAs obtained from DeFew cells at 72 h post-infection with retroviral vector expressing LMP1 or empty vector. The blot was analyzed for the expression of mature miR-155 and normalized by U6. (E) Graphic representation of the northern blot results as average of three independent experiments. (F) Western blot analysis of the expression of LMP1 upon infection with the retroviral vector. Input proteins were equalized by detecting the endogeneous gamma-tubulin.
###end p 43
###begin p 44
###xml 73 74 73 74 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 326 327 326 327 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 427 428 427 428 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</bold>
###xml 613 614 609 610 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">D</bold>
###xml 840 841 836 837 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E</bold>
###xml 941 942 937 938 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">F</bold>
###xml 46 49 <span type="species:ncbi:10376">EBV</span>
###xml 533 536 <span type="species:ncbi:10376">EBV</span>
LMP1 enhances the expression of miR-155 in an EBV-negative B-cell line. (A) A representative northern blot analysis on total RNAs obtained from DeFew cells transfected (TF) as indicated or untransfected (UT). The blot was analyzed for the expression of mature miR-155 and normalized by the ubiquitous small nuclear RNA (U6). (B) Graphic representation of the northern blot results as average of three independent experiments. (C) Western blot analysis of LMP1 expression in the transfected cells compared to MC3 cell immortalized by EBV. Input proteins were equalized by detecting the endogeneous gamma-tubulin. (D) Northern blot analysis of total RNAs obtained from DeFew cells at 72 h post-infection with retroviral vector expressing LMP1 or empty vector. The blot was analyzed for the expression of mature miR-155 and normalized by U6. (E) Graphic representation of the northern blot results as average of three independent experiments. (F) Western blot analysis of the expression of LMP1 upon infection with the retroviral vector. Input proteins were equalized by detecting the endogeneous gamma-tubulin.
###end p 44
###begin title 45
miR-155 expression can be driven through activation of two NF-kappaB elements in the BIC/miR-155 promoter
###end title 45
###begin p 46
###xml 327 329 323 325 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B27">27</xref>
###xml 422 424 418 420 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B27">27</xref>
###xml 449 452 445 448 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">cis</italic>
###xml 574 576 558 560 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B28">28</xref>
###xml 658 661 642 645 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">cis</italic>
###xml 991 994 963 966 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">cis</italic>
The foregoing results suggested that the LMP1-mediated induction of miR-155 occurred via a transcriptional mechanism. A recent study showed that the miR-155 promoter contains an AP-1 active site, located at 40 nt upstream from the TATA box and a NF-kappaB site located at 1150 nt upstream from the transcription starting site (27). The AP-1 active site plays a key role in activation of miR-155 expression induced by BCR (27). To identify potential cis-elements active on miR-155, we isolated a promoter region of approximately1.9 kb of the BIC gene, which encodes miR-155 (28), from MC3 cells and cloned it into a luciferase reporter plasmid. We looked for cis-element homologies using TESS () or TFSEARCH (), and identified some potential transcription factor binding sites, among which, an additional NF-kappaB site located at 1697 nt upstream from the transcription starting site (). Because NF-kappaB signaling plays a central role in B-cell physiology, we focused on the two NF-kappaB cis-elements.
###end p 46
###begin p 47
###xml 269 271 249 251 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B29">29</xref>
###xml 335 343 315 323 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F3">Figure 3</xref>
###xml 426 434 406 414 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F3">Figure 3</xref>
###xml 536 538 512 514 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B29">29</xref>
###xml 541 550 517 526 <label xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 3.</label>
###xml 620 621 596 597 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 901 902 877 878 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 907 908 883 884 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</bold>
###xml 550 995 526 971 <p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" textid="48">PMA induces miR-155 expression in a dose- and time-dependent manner. (<bold>A</bold>) Left: northern blot analysis of RNAs from DeFew cells treated with different concentrations of PMA; Right: northern blot analysis of RNAs from DeFew cells at different times upon PMA treatment. The blots were analyzed for the expression of mature miR-155 and normalized by U6. (<bold>B</bold> and <bold>C</bold>) Graphic representation of the average of three independent northern blot experiments.</p>
###xml 550 995 526 971 <caption xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><p textid="48">PMA induces miR-155 expression in a dose- and time-dependent manner. (<bold>A</bold>) Left: northern blot analysis of RNAs from DeFew cells treated with different concentrations of PMA; Right: northern blot analysis of RNAs from DeFew cells at different times upon PMA treatment. The blots were analyzed for the expression of mature miR-155 and normalized by U6. (<bold>B</bold> and <bold>C</bold>) Graphic representation of the average of three independent northern blot experiments.</p></caption>
###xml 995 995 971 971 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xlink:href="gkn666f3"/>
###xml 541 995 517 971 <fig xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="F3" position="float"><label>Figure 3.</label><caption><p textid="48">PMA induces miR-155 expression in a dose- and time-dependent manner. (<bold>A</bold>) Left: northern blot analysis of RNAs from DeFew cells treated with different concentrations of PMA; Right: northern blot analysis of RNAs from DeFew cells at different times upon PMA treatment. The blots were analyzed for the expression of mature miR-155 and normalized by U6. (<bold>B</bold> and <bold>C</bold>) Graphic representation of the average of three independent northern blot experiments.</p></caption><graphic xlink:href="gkn666f3"/></fig>
We next examined by northern blot the induction of miR-155 expression in DeFew cells treated with PMA, which induces NF-kappaB by activating protein kinase C (PKC) and related phosphorylation of inhibitor-kappaBalpha (IkappaBalpha), thereby leading to its degradation (29). PMA (25 ng/ml) increased miR-155 expression by about 3-fold (Figure 3A and B); miR-155 expression peaked 36 h after treatment and decreased thereafter (Figure 3A and C). The latter finding is in accordance with the pattern of PKC-activated NF-kappaB expression (29). Figure 3.PMA induces miR-155 expression in a dose- and time-dependent manner. (A) Left: northern blot analysis of RNAs from DeFew cells treated with different concentrations of PMA; Right: northern blot analysis of RNAs from DeFew cells at different times upon PMA treatment. The blots were analyzed for the expression of mature miR-155 and normalized by U6. (B and C) Graphic representation of the average of three independent northern blot experiments.
###end p 47
###begin p 48
###xml 70 71 70 71 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 351 352 351 352 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 357 358 357 358 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</bold>
PMA induces miR-155 expression in a dose- and time-dependent manner. (A) Left: northern blot analysis of RNAs from DeFew cells treated with different concentrations of PMA; Right: northern blot analysis of RNAs from DeFew cells at different times upon PMA treatment. The blots were analyzed for the expression of mature miR-155 and normalized by U6. (B and C) Graphic representation of the average of three independent northern blot experiments.
###end p 48
###begin title 49
###xml 74 82 66 74 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 87 94 79 86 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
The NF-kappaB elements in the BIC/miR-155 promoter bind NF-kappaB factors in vitro and in vivo in MC3 cells
###end title 49
###begin p 50
###xml 516 524 504 512 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F4">Figure 4</xref>
###xml 674 682 658 666 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F4">Figure 4</xref>
###xml 769 771 749 751 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B30">30</xref>
###xml 772 774 752 754 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B31">31</xref>
###xml 1137 1139 1105 1107 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B32">32</xref>
###xml 1203 1212 1167 1176 <label xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 4.</label>
###xml 1286 1294 1242 1250 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 1299 1306 1255 1262 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 1322 1323 1278 1279 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 1821 1822 1757 1758 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 2374 2375 2282 2283 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</bold>
###xml 1212 2891 1176 2795 <p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" textid="51">The two putative NF-&#954;B binding sites are bound by NF-&#954;B complexes <italic>in vitro</italic> and <italic>in vivo</italic> in MC3 cells. (<bold>A</bold>) Electrophoretic mobility shift assay using nuclear extracts from MC3 cells (EBV-positive cells) on the two NF-&#954;B binding sites. Left panel: NF-&#954;B site 1 (&#8722;1150). Right panel: NF-&#954;B site 2 (&#8722;1697). WT = 80-fold molar cold wild-type competitor; mut = 80-fold molar cold mutant competitor; U = 80-fold molar cold unspecific competitor; p50 = supershift with anti NF-&#954;B p50 antibody; p65 = supershift with anti NF-&#954;B p65 antibody. Supershift bands are indicated with red arrows. (<bold>B</bold>) ChIP assay of chromatin extracted from MC3 cells using polyclonal antibodies directed against the NF-&#954;B p65 or NF-&#954;B p50. After immunoprecipitation, the DNA samples were purified and subjected to PCR with specific primers amplifying the NF-&#954;B site 1 region (right panel) or NF-&#954;B site 2 region (left panel). MW = molecular weight marker; p65 = pAB anti NF-&#954;B p65; p50 = pAb anti NF-&#954;B p50; &#945;Rab = unspecific polyclonal antibody anti rabbit immunoglobulin; IP = input. The red arrows indicate the specific amplified band. (<bold>C</bold>) ChIP assay of chromatin extracted from MC3 cells using monoclonal antibody directed against the RNA pol II. After immunoprecipitation, the DNA samples were purified and subjected to PCR with specific primers amplifying the TATA box region. MW = molecular weight marker; pol II = mAB anti RNA pol II; IP = input. The two lanes represent two different amounts of input sample used for the PCR; &#945;Rab = unspecific polyclonal antibody anti rabbit immunoglobulin. The red arrow indicates the specific amplified band.</p>
###xml 1212 2891 1176 2795 <caption xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><p textid="51">The two putative NF-&#954;B binding sites are bound by NF-&#954;B complexes <italic>in vitro</italic> and <italic>in vivo</italic> in MC3 cells. (<bold>A</bold>) Electrophoretic mobility shift assay using nuclear extracts from MC3 cells (EBV-positive cells) on the two NF-&#954;B binding sites. Left panel: NF-&#954;B site 1 (&#8722;1150). Right panel: NF-&#954;B site 2 (&#8722;1697). WT = 80-fold molar cold wild-type competitor; mut = 80-fold molar cold mutant competitor; U = 80-fold molar cold unspecific competitor; p50 = supershift with anti NF-&#954;B p50 antibody; p65 = supershift with anti NF-&#954;B p65 antibody. Supershift bands are indicated with red arrows. (<bold>B</bold>) ChIP assay of chromatin extracted from MC3 cells using polyclonal antibodies directed against the NF-&#954;B p65 or NF-&#954;B p50. After immunoprecipitation, the DNA samples were purified and subjected to PCR with specific primers amplifying the NF-&#954;B site 1 region (right panel) or NF-&#954;B site 2 region (left panel). MW = molecular weight marker; p65 = pAB anti NF-&#954;B p65; p50 = pAb anti NF-&#954;B p50; &#945;Rab = unspecific polyclonal antibody anti rabbit immunoglobulin; IP = input. The red arrows indicate the specific amplified band. (<bold>C</bold>) ChIP assay of chromatin extracted from MC3 cells using monoclonal antibody directed against the RNA pol II. After immunoprecipitation, the DNA samples were purified and subjected to PCR with specific primers amplifying the TATA box region. MW = molecular weight marker; pol II = mAB anti RNA pol II; IP = input. The two lanes represent two different amounts of input sample used for the PCR; &#945;Rab = unspecific polyclonal antibody anti rabbit immunoglobulin. The red arrow indicates the specific amplified band.</p></caption>
###xml 2891 2891 2795 2795 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xlink:href="gkn666f4"/>
###xml 1203 2891 1167 2795 <fig xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="F4" position="float"><label>Figure 4.</label><caption><p textid="51">The two putative NF-&#954;B binding sites are bound by NF-&#954;B complexes <italic>in vitro</italic> and <italic>in vivo</italic> in MC3 cells. (<bold>A</bold>) Electrophoretic mobility shift assay using nuclear extracts from MC3 cells (EBV-positive cells) on the two NF-&#954;B binding sites. Left panel: NF-&#954;B site 1 (&#8722;1150). Right panel: NF-&#954;B site 2 (&#8722;1697). WT = 80-fold molar cold wild-type competitor; mut = 80-fold molar cold mutant competitor; U = 80-fold molar cold unspecific competitor; p50 = supershift with anti NF-&#954;B p50 antibody; p65 = supershift with anti NF-&#954;B p65 antibody. Supershift bands are indicated with red arrows. (<bold>B</bold>) ChIP assay of chromatin extracted from MC3 cells using polyclonal antibodies directed against the NF-&#954;B p65 or NF-&#954;B p50. After immunoprecipitation, the DNA samples were purified and subjected to PCR with specific primers amplifying the NF-&#954;B site 1 region (right panel) or NF-&#954;B site 2 region (left panel). MW = molecular weight marker; p65 = pAB anti NF-&#954;B p65; p50 = pAb anti NF-&#954;B p50; &#945;Rab = unspecific polyclonal antibody anti rabbit immunoglobulin; IP = input. The red arrows indicate the specific amplified band. (<bold>C</bold>) ChIP assay of chromatin extracted from MC3 cells using monoclonal antibody directed against the RNA pol II. After immunoprecipitation, the DNA samples were purified and subjected to PCR with specific primers amplifying the TATA box region. MW = molecular weight marker; pol II = mAB anti RNA pol II; IP = input. The two lanes represent two different amounts of input sample used for the PCR; &#945;Rab = unspecific polyclonal antibody anti rabbit immunoglobulin. The red arrow indicates the specific amplified band.</p></caption><graphic xlink:href="gkn666f4"/></fig>
###xml 1401 1404 <span type="species:ncbi:10376">EBV</span>
###xml 2285 2291 <span type="species:ncbi:9986">rabbit</span>
###xml 2816 2822 <span type="species:ncbi:9986">rabbit</span>
To determine the activity of the two NF-kappaB elements identified in the miR-155 promoter, we performed EMSA using nuclear extracts from MC3 cells. Briefly, the nuclear extracts were incubated with dsDNA oligonucleotides identical to the sequence of the NF-kappaB site 1 (-1150) or 2 (-1697). Both sites underwent an electrophoretic mobility shift, which disappeared when we used a 80-fold molar cold competitor, but not when we used the same amount of a mutant competitor that is not bound by NF-kappaB complexes (Figure 4A). There was a supershift when the nuclear proteins were pre-incubated with antibodies against p65/RelA or p50, two members of the NF-kappaB family (Figure 4A). Because LMP1 could activate the p52/p65 NF-kappaB complex (non-canonical pathway) (30,31), we repeated the experiment using an anti p52 antibody, and found no supershift under these conditions (data not shown). In line with the hypothesis that the canonical NF-kappaB pathway is involved in the LMP1-mediated activation of miR-155, we found that miR-155 expression was inhibited in MC3 cell expressing an exogenous, undegradable form of IkappaBalpha (32), which is an inhibitor of the canonical NF-kappaB pathway (). Figure 4.The two putative NF-kappaB binding sites are bound by NF-kappaB complexes in vitro and in vivo in MC3 cells. (A) Electrophoretic mobility shift assay using nuclear extracts from MC3 cells (EBV-positive cells) on the two NF-kappaB binding sites. Left panel: NF-kappaB site 1 (-1150). Right panel: NF-kappaB site 2 (-1697). WT = 80-fold molar cold wild-type competitor; mut = 80-fold molar cold mutant competitor; U = 80-fold molar cold unspecific competitor; p50 = supershift with anti NF-kappaB p50 antibody; p65 = supershift with anti NF-kappaB p65 antibody. Supershift bands are indicated with red arrows. (B) ChIP assay of chromatin extracted from MC3 cells using polyclonal antibodies directed against the NF-kappaB p65 or NF-kappaB p50. After immunoprecipitation, the DNA samples were purified and subjected to PCR with specific primers amplifying the NF-kappaB site 1 region (right panel) or NF-kappaB site 2 region (left panel). MW = molecular weight marker; p65 = pAB anti NF-kappaB p65; p50 = pAb anti NF-kappaB p50; alphaRab = unspecific polyclonal antibody anti rabbit immunoglobulin; IP = input. The red arrows indicate the specific amplified band. (C) ChIP assay of chromatin extracted from MC3 cells using monoclonal antibody directed against the RNA pol II. After immunoprecipitation, the DNA samples were purified and subjected to PCR with specific primers amplifying the TATA box region. MW = molecular weight marker; pol II = mAB anti RNA pol II; IP = input. The two lanes represent two different amounts of input sample used for the PCR; alphaRab = unspecific polyclonal antibody anti rabbit immunoglobulin. The red arrow indicates the specific amplified band.
###end p 50
###begin p 51
###xml 74 82 66 74 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 87 94 79 86 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 110 111 102 103 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 609 610 581 582 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 1162 1163 1106 1107 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</bold>
###xml 189 192 <span type="species:ncbi:10376">EBV</span>
###xml 1073 1079 <span type="species:ncbi:9986">rabbit</span>
###xml 1604 1610 <span type="species:ncbi:9986">rabbit</span>
The two putative NF-kappaB binding sites are bound by NF-kappaB complexes in vitro and in vivo in MC3 cells. (A) Electrophoretic mobility shift assay using nuclear extracts from MC3 cells (EBV-positive cells) on the two NF-kappaB binding sites. Left panel: NF-kappaB site 1 (-1150). Right panel: NF-kappaB site 2 (-1697). WT = 80-fold molar cold wild-type competitor; mut = 80-fold molar cold mutant competitor; U = 80-fold molar cold unspecific competitor; p50 = supershift with anti NF-kappaB p50 antibody; p65 = supershift with anti NF-kappaB p65 antibody. Supershift bands are indicated with red arrows. (B) ChIP assay of chromatin extracted from MC3 cells using polyclonal antibodies directed against the NF-kappaB p65 or NF-kappaB p50. After immunoprecipitation, the DNA samples were purified and subjected to PCR with specific primers amplifying the NF-kappaB site 1 region (right panel) or NF-kappaB site 2 region (left panel). MW = molecular weight marker; p65 = pAB anti NF-kappaB p65; p50 = pAb anti NF-kappaB p50; alphaRab = unspecific polyclonal antibody anti rabbit immunoglobulin; IP = input. The red arrows indicate the specific amplified band. (C) ChIP assay of chromatin extracted from MC3 cells using monoclonal antibody directed against the RNA pol II. After immunoprecipitation, the DNA samples were purified and subjected to PCR with specific primers amplifying the TATA box region. MW = molecular weight marker; pol II = mAB anti RNA pol II; IP = input. The two lanes represent two different amounts of input sample used for the PCR; alphaRab = unspecific polyclonal antibody anti rabbit immunoglobulin. The red arrow indicates the specific amplified band.
###end p 51
###begin p 52
###xml 64 71 60 67 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 252 260 240 248 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F4">Figure 4</xref>
###xml 466 468 454 456 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B33">33</xref>
###xml 585 593 573 581 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F4">Figure 4</xref>
###xml 674 682 662 670 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F4">Figure 4</xref>
To determine whether the NF-kappaB p50/p65 complex is recruited in vivo on the BIC/miR-155 promoter, we examined the two NF-kappaB sites by chromatin immunoprecipitation assay (ChIP). We show that p65 but not p50 is engaged on the two NF-kappaB sites (Figure 4B). However, we cannot rule out that p50 contributes to the active complex because it could simply be covered by DNA and p65, and thus inaccessible to the antibody. RNA pol II drives miR-155 transcription (33). Therefore, we checked, in the same experiment if the BIC promoter was also engaged by the RNA pol II. As shown in Figure 4C we found the RNA polymerase on the TATA box of BIC promoter together with p65 (Figure 4C).
###end p 52
###begin title 53
###xml 31 34 27 30 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">cis</italic>
LMP1 requires intact NF-kappaB cis-elements to enhance miR-155 expression
###end title 53
###begin p 54
###xml 266 267 258 259 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B6">6</xref>
###xml 268 272 260 264 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B8 B9 B10">8&#8211;10</xref>
###xml 305 308 297 300 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">cis</italic>
###xml 372 374 364 366 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B27">27</xref>
###xml 554 562 546 554 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F5">Figure 5</xref>
###xml 573 581 565 573 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F6">Figure 6</xref>
###xml 737 740 721 724 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">cis</italic>
###xml 1223 1231 1167 1175 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F6">Figure 6</xref>
###xml 1498 1506 1430 1438 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F6">Figure 6</xref>
###xml 1964 1972 1876 1884 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F6">Figure 6</xref>
###xml 2152 2160 2064 2072 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F6">Figure 6</xref>
###xml 2216 2224 2128 2136 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F5">Figure 5</xref>
###xml 2391 2399 2283 2291 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F6">Figure 6</xref>
###xml 2416 2424 2308 2316 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F6">Figure 6</xref>
###xml 2819 2827 2707 2715 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F6">Figure 6</xref>
###xml 2884 2893 2772 2781 <label xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 5.</label>
###xml 2893 3361 2781 3249 <p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" textid="55">Truncated form of the BIC promoter (pLuc1380) is the most inducible by PMA. Luciferase assay performed in De Few cells using the full-length miR-155 promoter and two truncated forms. The transfected cells were treated or mock treated with 25 ng/ml of PMA. In presence of PMA the truncated form of the BIC promoter (pLuc1380) reaches the maximum of luciferase activity. The graphic representation of the luciferase assay is the average of three independent experiments.</p>
###xml 2893 3361 2781 3249 <caption xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><p textid="55">Truncated form of the BIC promoter (pLuc1380) is the most inducible by PMA. Luciferase assay performed in De Few cells using the full-length miR-155 promoter and two truncated forms. The transfected cells were treated or mock treated with 25 ng/ml of PMA. In presence of PMA the truncated form of the BIC promoter (pLuc1380) reaches the maximum of luciferase activity. The graphic representation of the luciferase assay is the average of three independent experiments.</p></caption>
###xml 3361 3361 3249 3249 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xlink:href="gkn666f5"/>
###xml 2884 3361 2772 3249 <fig xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="F5" position="float"><label>Figure 5.</label><caption><p textid="55">Truncated form of the BIC promoter (pLuc1380) is the most inducible by PMA. Luciferase assay performed in De Few cells using the full-length miR-155 promoter and two truncated forms. The transfected cells were treated or mock treated with 25 ng/ml of PMA. In presence of PMA the truncated form of the BIC promoter (pLuc1380) reaches the maximum of luciferase activity. The graphic representation of the luciferase assay is the average of three independent experiments.</p></caption><graphic xlink:href="gkn666f5"/></fig>
###xml 3361 3370 3249 3258 <label xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 6.</label>
###xml 3380 3383 3264 3267 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">cis</italic>
###xml 3467 3468 3351 3352 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 3473 3474 3357 3358 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 3737 3738 3617 3618 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</bold>
###xml 3370 3841 3258 3717 <p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" textid="56">NF-&#954;B <italic>cis</italic>-elements are essential for basal and LMP1-mediated activation of miR-155 pomoter. (<bold>A</bold> and <bold>B</bold>) The indicated miR-155 promoter luciferase vectors were co-transfected with pBABEpuroLMP1 or empty vector and incubated for 48 h. Luciferase expression was normalized by &#946;-gal/&#956;g of total protein and represented as average of three independent experiments. (<bold>C</bold>) Western blot analysis of LMP1 expression in the co-transfected MEF cells, normalized by &#947;tubulin.</p>
###xml 3370 3841 3258 3717 <caption xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><p textid="56">NF-&#954;B <italic>cis</italic>-elements are essential for basal and LMP1-mediated activation of miR-155 pomoter. (<bold>A</bold> and <bold>B</bold>) The indicated miR-155 promoter luciferase vectors were co-transfected with pBABEpuroLMP1 or empty vector and incubated for 48 h. Luciferase expression was normalized by &#946;-gal/&#956;g of total protein and represented as average of three independent experiments. (<bold>C</bold>) Western blot analysis of LMP1 expression in the co-transfected MEF cells, normalized by &#947;tubulin.</p></caption>
###xml 3841 3841 3717 3717 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xlink:href="gkn666f6"/>
###xml 3361 3841 3249 3717 <fig xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="F6" position="float"><label>Figure 6.</label><caption><p textid="56">NF-&#954;B <italic>cis</italic>-elements are essential for basal and LMP1-mediated activation of miR-155 pomoter. (<bold>A</bold> and <bold>B</bold>) The indicated miR-155 promoter luciferase vectors were co-transfected with pBABEpuroLMP1 or empty vector and incubated for 48 h. Luciferase expression was normalized by &#946;-gal/&#956;g of total protein and represented as average of three independent experiments. (<bold>C</bold>) Western blot analysis of LMP1 expression in the co-transfected MEF cells, normalized by &#947;tubulin.</p></caption><graphic xlink:href="gkn666f6"/></fig>
###xml 1193 1196 <span type="species:ncbi:10376">EBV</span>
The foregoing experiments provide compelling evidence that LMP1 drives miR-155 upregulation and that the miR promoter responds to NF-kappaB transacting factors. However, LMP1 can activate two different pathways: the NF-kappaB pathway and the Jun/Fos (AP-1) pathway (6,8-10) and the miR-155 promoter has a cis-element responsive to AP-1 40 nt upstream from the start site (27). Using truncated forms of BIC promoter cloned upstream the luciferase gene reporter, we observed that only the first 1380 nt drive the maximum activation of the promoter by PMA (Figure 5) or LMP1 (Figure 6). This could indicate that the NF-kappaB site 2 is irrelevant in the LMP1-mediated activation of miR-155. To verify the effectiveness of the two NF-kappaB cis-elements in LMP1-enhanced miR-155 promoter, we used both the promoters cloned upstream luciferase gene reporter [pLuc1783 wild-type (wt) and pLuc1380 wt]. Subsequently, we mutated NF-kappaB site 1 (pLuc1783DeltaNF-kappaB1 and pLuc1380DeltaNF-kappaB), the AP-1 site (pLuc1783DeltaAP-1 and pLuc1380DeltaAP-1) and the NF-kappaB site 2 (pLuc1783DeltaNF-kappaB2) using site-directed mutagenesis. All vectors were used for transfection and reporter assay in EBV-negative MEF. As shown in Figure 6A, pLuc1380 wt was upregulated by about 5-fold when cotransfected with a vector expressing LMP1. In the presence of LMP1, pLuc1380DeltaNF-kappaB expression was about 80-fold less, and the expression of pLuc1380DeltaAP-1 about 6-fold less than pLuc1380 wt expression (Figure 6A). These data would suggest that NF-kappaB site 1 plays a pivotal role in LMP1 activation and that substantial cooperation by the AP-1 site is required to attain maximum activation. Consistent with these results, NF-kappaB seems to be central also for basal levels of miR-155 expression. Indeed, without LMP1, pLuc1380DeltaNF-kappaB expression was about 17-fold lower than pLuc1380 wt expression, whereas pLuc1380DeltaAP1 was downregulated by about 3-fold (Figure 6A). When the reporter assays were repeated using the full-length vector pLuc1783 wt, induction was reduced (about 3-fold), in the presence of LMP1 compared to pLuc1380 wt (compare Figure 6A and B), which is in line with the results reported in Figure 5. Surprisingly, all mutated forms of this vector (pLuc1783DeltaNF-kappaB2, pLuc1783DeltaNF-kappaB1 and pLuc1783DeltaAP-1) were no longer activated by LMP1 expression (Figure 6B). The graph in Figure 6B is presented in logarithmic scale in order to show that the mutations in both NF-kappaB sites dramatically reduced the basal level of miR-155 promoter-driven luciferase expression, whereas the AP-1 mutation reduced basal levels to a much lesser extent. The latter observation is consistent with our data obtained with the truncated promoter. The expression of LMP1 was checked in each sample (Figure 6C) for a further normalization of the luciferase assays. Figure 5.Truncated form of the BIC promoter (pLuc1380) is the most inducible by PMA. Luciferase assay performed in De Few cells using the full-length miR-155 promoter and two truncated forms. The transfected cells were treated or mock treated with 25 ng/ml of PMA. In presence of PMA the truncated form of the BIC promoter (pLuc1380) reaches the maximum of luciferase activity. The graphic representation of the luciferase assay is the average of three independent experiments.Figure 6.NF-kappaB cis-elements are essential for basal and LMP1-mediated activation of miR-155 pomoter. (A and B) The indicated miR-155 promoter luciferase vectors were co-transfected with pBABEpuroLMP1 or empty vector and incubated for 48 h. Luciferase expression was normalized by beta-gal/mug of total protein and represented as average of three independent experiments. (C) Western blot analysis of LMP1 expression in the co-transfected MEF cells, normalized by gammatubulin.
###end p 54
###begin p 55
Truncated form of the BIC promoter (pLuc1380) is the most inducible by PMA. Luciferase assay performed in De Few cells using the full-length miR-155 promoter and two truncated forms. The transfected cells were treated or mock treated with 25 ng/ml of PMA. In presence of PMA the truncated form of the BIC promoter (pLuc1380) reaches the maximum of luciferase activity. The graphic representation of the luciferase assay is the average of three independent experiments.
###end p 55
###begin p 56
###xml 10 13 6 9 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">cis</italic>
###xml 97 98 93 94 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 103 104 99 100 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 367 368 359 360 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</bold>
NF-kappaB cis-elements are essential for basal and LMP1-mediated activation of miR-155 pomoter. (A and B) The indicated miR-155 promoter luciferase vectors were co-transfected with pBABEpuroLMP1 or empty vector and incubated for 48 h. Luciferase expression was normalized by beta-gal/mug of total protein and represented as average of three independent experiments. (C) Western blot analysis of LMP1 expression in the co-transfected MEF cells, normalized by gammatubulin.
###end p 56
###begin p 57
###xml 40 43 36 39 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">cis</italic>
###xml 203 206 199 202 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">cis</italic>
These data indicate that both NF-kappaB cis-elements play a central role in LMP1-mediated activation of the promoter and may suggest the possible presence of a negative regulatory region between the two cis-elements.
###end p 57
###begin title 58
###xml 42 45 38 41 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">cis</italic>
The binding of p65/RelA to both NF-kappaB cis-elements of miR-155 promoter is temporally correlated to LMP1 expression
###end title 58
###begin p 59
###xml 420 428 420 428 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F7">Figure 7</xref>
###xml 529 537 529 537 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F7">Figure 7</xref>
###xml 654 662 654 662 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F7">Figure 7</xref>
###xml 666 675 666 675 <label xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 7.</label>
###xml 728 729 728 729 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 942 943 938 939 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 998 999 994 995 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</bold>
###xml 1217 1218 1213 1214 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">D</bold>
###xml 1274 1275 1270 1271 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E</bold>
###xml 675 1369 675 1365 <p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" textid="60">Time-course of LMP1-mediated activation of miR-155. (<bold>A</bold>) Western blot analysis of protein extracts obtained at indicated times from DeFew cells infected with pBABEpuroLMP1 or empty vector. The blot was analyzed for the expression of LMP1 and normalized by &#947;-tub. (<bold>B</bold>) Graphic representation of the western blot results. (<bold>C</bold>) Northern blot analysis of RNAs obtained at indicated times from DeFew cells infected with retroviral vector expressing LMP1 or empty vector. The blot was analyzed for the expression of miR-155 and normalized by U6. (<bold>D</bold>) Graphic representation of the northern blot results. (<bold>E</bold>) Graphic representation of the correlation of miR-155 and LMP1 expression at indicated times.</p>
###xml 675 1369 675 1365 <caption xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><p textid="60">Time-course of LMP1-mediated activation of miR-155. (<bold>A</bold>) Western blot analysis of protein extracts obtained at indicated times from DeFew cells infected with pBABEpuroLMP1 or empty vector. The blot was analyzed for the expression of LMP1 and normalized by &#947;-tub. (<bold>B</bold>) Graphic representation of the western blot results. (<bold>C</bold>) Northern blot analysis of RNAs obtained at indicated times from DeFew cells infected with retroviral vector expressing LMP1 or empty vector. The blot was analyzed for the expression of miR-155 and normalized by U6. (<bold>D</bold>) Graphic representation of the northern blot results. (<bold>E</bold>) Graphic representation of the correlation of miR-155 and LMP1 expression at indicated times.</p></caption>
###xml 1369 1369 1365 1365 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xlink:href="gkn666f7"/>
###xml 666 1369 666 1365 <fig xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="F7" position="float"><label>Figure 7.</label><caption><p textid="60">Time-course of LMP1-mediated activation of miR-155. (<bold>A</bold>) Western blot analysis of protein extracts obtained at indicated times from DeFew cells infected with pBABEpuroLMP1 or empty vector. The blot was analyzed for the expression of LMP1 and normalized by &#947;-tub. (<bold>B</bold>) Graphic representation of the western blot results. (<bold>C</bold>) Northern blot analysis of RNAs obtained at indicated times from DeFew cells infected with retroviral vector expressing LMP1 or empty vector. The blot was analyzed for the expression of miR-155 and normalized by U6. (<bold>D</bold>) Graphic representation of the northern blot results. (<bold>E</bold>) Graphic representation of the correlation of miR-155 and LMP1 expression at indicated times.</p></caption><graphic xlink:href="gkn666f7"/></fig>
To determine whether the exogenous expression of LMP1, in DeFew cells, is correlated temporally with the upregulation of the endogenous miR-155, we performed a time-course experiment in DeFew cells infected with pBABEpuroLMP1 or with the empty vector as control. Each time point was split into three for western blot, northern blot and ChIP analyses. LMP1 expression was observed 24 h post-infection and peaked at 72 h (Figure 7A and B), whereas the upregulation of miR-155 occurred at 48 h post-infection and increased at 72 h (Figure 7C and D). These results indicate that the upregulation of miR-155 is temporally dependent on the expression of LMP1 (Figure 7E). Figure 7.Time-course of LMP1-mediated activation of miR-155. (A) Western blot analysis of protein extracts obtained at indicated times from DeFew cells infected with pBABEpuroLMP1 or empty vector. The blot was analyzed for the expression of LMP1 and normalized by gamma-tub. (B) Graphic representation of the western blot results. (C) Northern blot analysis of RNAs obtained at indicated times from DeFew cells infected with retroviral vector expressing LMP1 or empty vector. The blot was analyzed for the expression of miR-155 and normalized by U6. (D) Graphic representation of the northern blot results. (E) Graphic representation of the correlation of miR-155 and LMP1 expression at indicated times.
###end p 59
###begin p 60
###xml 53 54 53 54 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 267 268 263 264 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 323 324 319 320 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</bold>
###xml 542 543 538 539 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">D</bold>
###xml 599 600 595 596 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E</bold>
Time-course of LMP1-mediated activation of miR-155. (A) Western blot analysis of protein extracts obtained at indicated times from DeFew cells infected with pBABEpuroLMP1 or empty vector. The blot was analyzed for the expression of LMP1 and normalized by gamma-tub. (B) Graphic representation of the western blot results. (C) Northern blot analysis of RNAs obtained at indicated times from DeFew cells infected with retroviral vector expressing LMP1 or empty vector. The blot was analyzed for the expression of miR-155 and normalized by U6. (D) Graphic representation of the northern blot results. (E) Graphic representation of the correlation of miR-155 and LMP1 expression at indicated times.
###end p 60
###begin p 61
###xml 53 56 49 52 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">cis</italic>
###xml 57 65 53 61 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">elements</italic>
###xml 232 240 224 232 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F8">Figure 8</xref>
###xml 258 266 250 258 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F8">Figure 8</xref>
###xml 345 353 337 345 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F8">Figure 8</xref>
###xml 505 513 493 501 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F8">Figure 8</xref>
###xml 531 539 519 527 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F8">Figure 8</xref>
###xml 648 656 632 640 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F8">Figure 8</xref>
###xml 674 682 658 666 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F8">Figure 8</xref>
###xml 836 844 820 828 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F8">Figure 8</xref>
###xml 943 951 927 935 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F8">Figure 8</xref>
###xml 1029 1037 1013 1021 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F7">Figure 7</xref>
###xml 1156 1165 1140 1149 <label xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 8.</label>
###xml 1436 1437 1420 1421 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 1893 1894 1865 1866 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 1165 2200 1149 2172 <p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" textid="62">Semi-quantitative ChIP on the BIC promoter at indicated times in DeFew cells after retroviral infection with a vector expressing LMP1 or empty vector. ChIP assay of chromatin extracted at the indicated times from DeFew cells infected with pBABEpuroLMP1 or empty vector. (<bold>A</bold>) left panel: After immunoprecipitation with the indicated antibodies, the DNA samples were purified and subjected to PCR with specific primers amplifying the NF-&#954;B site 1 region or NF-&#954;B site 2 region. MW = molecular weight marker; p65 = pAB anti NF-&#954;B p65; ti NF; H3 = pAb anti Histone H3. Right panel: After immunoprecipitation, the DNA samples were purified and subjected to PCR with specific primers amplifying the G3PDH promoter region. (<bold>B</bold>) Graphic of the results showed in panel (A; C) After immunoprecipitation with mAb directed against the RNA pol II, the DNA samples were purified and subjected to PCR with specific primers amplifying the TATA box region. MW = molecular weight marker; pol II = mAB anti RNA pol II; H3 = pAb anti Histone H3.</p>
###xml 1165 2200 1149 2172 <caption xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><p textid="62">Semi-quantitative ChIP on the BIC promoter at indicated times in DeFew cells after retroviral infection with a vector expressing LMP1 or empty vector. ChIP assay of chromatin extracted at the indicated times from DeFew cells infected with pBABEpuroLMP1 or empty vector. (<bold>A</bold>) left panel: After immunoprecipitation with the indicated antibodies, the DNA samples were purified and subjected to PCR with specific primers amplifying the NF-&#954;B site 1 region or NF-&#954;B site 2 region. MW = molecular weight marker; p65 = pAB anti NF-&#954;B p65; ti NF; H3 = pAb anti Histone H3. Right panel: After immunoprecipitation, the DNA samples were purified and subjected to PCR with specific primers amplifying the G3PDH promoter region. (<bold>B</bold>) Graphic of the results showed in panel (A; C) After immunoprecipitation with mAb directed against the RNA pol II, the DNA samples were purified and subjected to PCR with specific primers amplifying the TATA box region. MW = molecular weight marker; pol II = mAB anti RNA pol II; H3 = pAb anti Histone H3.</p></caption>
###xml 2200 2200 2172 2172 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xlink:href="gkn666f8"/>
###xml 1156 2200 1140 2172 <fig xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="F8" position="float"><label>Figure 8.</label><caption><p textid="62">Semi-quantitative ChIP on the BIC promoter at indicated times in DeFew cells after retroviral infection with a vector expressing LMP1 or empty vector. ChIP assay of chromatin extracted at the indicated times from DeFew cells infected with pBABEpuroLMP1 or empty vector. (<bold>A</bold>) left panel: After immunoprecipitation with the indicated antibodies, the DNA samples were purified and subjected to PCR with specific primers amplifying the NF-&#954;B site 1 region or NF-&#954;B site 2 region. MW = molecular weight marker; p65 = pAB anti NF-&#954;B p65; ti NF; H3 = pAb anti Histone H3. Right panel: After immunoprecipitation, the DNA samples were purified and subjected to PCR with specific primers amplifying the G3PDH promoter region. (<bold>B</bold>) Graphic of the results showed in panel (A; C) After immunoprecipitation with mAb directed against the RNA pol II, the DNA samples were purified and subjected to PCR with specific primers amplifying the TATA box region. MW = molecular weight marker; pol II = mAB anti RNA pol II; H3 = pAb anti Histone H3.</p></caption><graphic xlink:href="gkn666f8"/></fig>
To further clarify the function of the two NF-kappaB cis-elements in the endogenous miR-155 promoter, we performed ChIP analysis followed by semi-quantitative PCR. There was constitutive binding of p65/RelA on both NF-kappaB sites (Figure 8A, left panel and Figure 8B). This binding did not increase in the cells infected with the empty vector (Figure 8A, left panel). In contrast, in the cells expressing LMP1, the binding of p65/RelA on NF-kappaB 1 site increased 1.5-fold at 24 h and 3.5-fold at 72 h (Figure 8A, left panel and Figure 8B), whereas the binding of p65/RelA on the NF-kappaB 2 site increased 1.3-fold at 24 h and 2.5-fold at 72 h (Figure 8A, left panel and Figure 8B). At the same time points, the binding of RNA pol II on the TATA box of BIC promoter increased in the LMP1-infected cells but not in the control cells (Figure 8C left panel). G3PDH was used as negative control and the assay was normalized against histone H3 (Figure 8A and C, right panel). Taken together, these data and the results reported in Figure 7 strongly suggest that LMP1 activates p65 binding on miR-155 promoter and this lead to upregulation of miR expression. Figure 8.Semi-quantitative ChIP on the BIC promoter at indicated times in DeFew cells after retroviral infection with a vector expressing LMP1 or empty vector. ChIP assay of chromatin extracted at the indicated times from DeFew cells infected with pBABEpuroLMP1 or empty vector. (A) left panel: After immunoprecipitation with the indicated antibodies, the DNA samples were purified and subjected to PCR with specific primers amplifying the NF-kappaB site 1 region or NF-kappaB site 2 region. MW = molecular weight marker; p65 = pAB anti NF-kappaB p65; ti NF; H3 = pAb anti Histone H3. Right panel: After immunoprecipitation, the DNA samples were purified and subjected to PCR with specific primers amplifying the G3PDH promoter region. (B) Graphic of the results showed in panel (A; C) After immunoprecipitation with mAb directed against the RNA pol II, the DNA samples were purified and subjected to PCR with specific primers amplifying the TATA box region. MW = molecular weight marker; pol II = mAB anti RNA pol II; H3 = pAb anti Histone H3.
###end p 61
###begin p 62
###xml 271 272 271 272 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 728 729 716 717 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
Semi-quantitative ChIP on the BIC promoter at indicated times in DeFew cells after retroviral infection with a vector expressing LMP1 or empty vector. ChIP assay of chromatin extracted at the indicated times from DeFew cells infected with pBABEpuroLMP1 or empty vector. (A) left panel: After immunoprecipitation with the indicated antibodies, the DNA samples were purified and subjected to PCR with specific primers amplifying the NF-kappaB site 1 region or NF-kappaB site 2 region. MW = molecular weight marker; p65 = pAB anti NF-kappaB p65; ti NF; H3 = pAb anti Histone H3. Right panel: After immunoprecipitation, the DNA samples were purified and subjected to PCR with specific primers amplifying the G3PDH promoter region. (B) Graphic of the results showed in panel (A; C) After immunoprecipitation with mAb directed against the RNA pol II, the DNA samples were purified and subjected to PCR with specific primers amplifying the TATA box region. MW = molecular weight marker; pol II = mAB anti RNA pol II; H3 = pAb anti Histone H3.
###end p 62
###begin title 63
The protein levels of transcription factor PU.1 correlates with LMP1-induced miR-155 expression
###end title 63
###begin p 64
###xml 91 93 91 93 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B35">35</xref>
###xml 449 457 449 457 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F9">Figure 9</xref>
###xml 567 575 567 575 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F9">Figure 9</xref>
###xml 773 782 773 782 <label xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 9.</label>
###xml 865 866 865 866 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 1100 1101 1100 1101 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 1171 1172 1167 1168 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</bold>
###xml 1409 1410 1405 1406 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">D</bold>
###xml 782 1466 782 1462 <p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" textid="65">PU.1 protein levels correlate with LMP1-mediated activation of miR-155 expression (<bold>A</bold>) western blot analysis of PU.1 expression in EBV-immortalized B cells (MC3) EBV-negative B cells (DeFew) infected with pBABEpuroLMP1 (DeFew LMP1) or pBABEpuro, and selected with 1 mg/ml of puromycin for 7 days (DeFew Empty Vector); (<bold>B</bold>) Graph of densitometric analysis of A normalized by &#947;-tubuline; (<bold>C</bold>) northern blot analysis of mir-155 expression in EBV-immortalized B cells (MC3) EBV-negative B cells (DeFew) infected with pBABEpuroLMP1 (DeFew LMP1) or pBABEpuro (DeFew Empty Vector) and selected with 1 mg/ml of puromycin for 7 days; (<bold>D</bold>) Graph of densitometric analysis of C normalized by U6.</p>
###xml 782 1466 782 1462 <caption xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><p textid="65">PU.1 protein levels correlate with LMP1-mediated activation of miR-155 expression (<bold>A</bold>) western blot analysis of PU.1 expression in EBV-immortalized B cells (MC3) EBV-negative B cells (DeFew) infected with pBABEpuroLMP1 (DeFew LMP1) or pBABEpuro, and selected with 1 mg/ml of puromycin for 7 days (DeFew Empty Vector); (<bold>B</bold>) Graph of densitometric analysis of A normalized by &#947;-tubuline; (<bold>C</bold>) northern blot analysis of mir-155 expression in EBV-immortalized B cells (MC3) EBV-negative B cells (DeFew) infected with pBABEpuroLMP1 (DeFew LMP1) or pBABEpuro (DeFew Empty Vector) and selected with 1 mg/ml of puromycin for 7 days; (<bold>D</bold>) Graph of densitometric analysis of C normalized by U6.</p></caption>
###xml 1466 1466 1462 1462 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xlink:href="gkn666f9"/>
###xml 773 1466 773 1462 <fig xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="F9" position="float"><label>Figure 9.</label><caption><p textid="65">PU.1 protein levels correlate with LMP1-mediated activation of miR-155 expression (<bold>A</bold>) western blot analysis of PU.1 expression in EBV-immortalized B cells (MC3) EBV-negative B cells (DeFew) infected with pBABEpuroLMP1 (DeFew LMP1) or pBABEpuro, and selected with 1 mg/ml of puromycin for 7 days (DeFew Empty Vector); (<bold>B</bold>) Graph of densitometric analysis of A normalized by &#947;-tubuline; (<bold>C</bold>) northern blot analysis of mir-155 expression in EBV-immortalized B cells (MC3) EBV-negative B cells (DeFew) infected with pBABEpuroLMP1 (DeFew LMP1) or pBABEpuro (DeFew Empty Vector) and selected with 1 mg/ml of puromycin for 7 days; (<bold>D</bold>) Graph of densitometric analysis of C normalized by U6.</p></caption><graphic xlink:href="gkn666f9"/></fig>
###xml 723 726 <span type="species:ncbi:10376">EBV</span>
###xml 912 915 <span type="species:ncbi:10376">EBV</span>
###xml 943 946 <span type="species:ncbi:10376">EBV</span>
###xml 1222 1225 <span type="species:ncbi:10376">EBV</span>
###xml 1253 1256 <span type="species:ncbi:10376">EBV</span>
It was recently reported that miR-155 targets PU.1 mRNA thereby affecting its translation (35). Hence, we checked whether the levels of protein PU.1 could be lowered by LMP1 activation of miR-155. To this aim, we infected DeFew cells with the retroviral vector expressing LMP1 or with the empty vector as control. The results show a 2-fold decrease of PU.1 protein levels in the DeFew cells infected with LMP1-expressing vector versus empty vector (Figure 9A and B). In the same experiment, we ran a northern blot analysis to evaluate miR-155 expression. As shown in Figure 9C and D, miR-155 expression in LMP1-expressing DeFew cells was 10-fold higher than in the empty vector. Interestingly, PU-1 levels were very low in EBV-immortalized MC3 cells overexpressing miR-155 Figure 9.PU.1 protein levels correlate with LMP1-mediated activation of miR-155 expression (A) western blot analysis of PU.1 expression in EBV-immortalized B cells (MC3) EBV-negative B cells (DeFew) infected with pBABEpuroLMP1 (DeFew LMP1) or pBABEpuro, and selected with 1 mg/ml of puromycin for 7 days (DeFew Empty Vector); (B) Graph of densitometric analysis of A normalized by gamma-tubuline; (C) northern blot analysis of mir-155 expression in EBV-immortalized B cells (MC3) EBV-negative B cells (DeFew) infected with pBABEpuroLMP1 (DeFew LMP1) or pBABEpuro (DeFew Empty Vector) and selected with 1 mg/ml of puromycin for 7 days; (D) Graph of densitometric analysis of C normalized by U6.
###end p 64
###begin p 65
###xml 83 84 83 84 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 318 319 318 319 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 389 390 385 386 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</bold>
###xml 627 628 623 624 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">D</bold>
###xml 130 133 <span type="species:ncbi:10376">EBV</span>
###xml 161 164 <span type="species:ncbi:10376">EBV</span>
###xml 440 443 <span type="species:ncbi:10376">EBV</span>
###xml 471 474 <span type="species:ncbi:10376">EBV</span>
PU.1 protein levels correlate with LMP1-mediated activation of miR-155 expression (A) western blot analysis of PU.1 expression in EBV-immortalized B cells (MC3) EBV-negative B cells (DeFew) infected with pBABEpuroLMP1 (DeFew LMP1) or pBABEpuro, and selected with 1 mg/ml of puromycin for 7 days (DeFew Empty Vector); (B) Graph of densitometric analysis of A normalized by gamma-tubuline; (C) northern blot analysis of mir-155 expression in EBV-immortalized B cells (MC3) EBV-negative B cells (DeFew) infected with pBABEpuroLMP1 (DeFew LMP1) or pBABEpuro (DeFew Empty Vector) and selected with 1 mg/ml of puromycin for 7 days; (D) Graph of densitometric analysis of C normalized by U6.
###end p 65
###begin title 66
DISCUSSION
###end title 66
###begin p 67
###xml 390 392 390 392 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B33">33</xref>
microRNAs, like transcription factors, regulate the expression of several genes post-transcriptionally, and are thus important players in such relevant cellular processes as cell growth, differentiation, cell signaling and apoptosis [see (11) for a review]. miRNAs themselves are subjected to fine expression regulation, their transcription being driven by RNA pol II responsive promoters (33). It is generally recognized that miRNAs play a central role in the molecular etiology and maintenance of cancer.
###end p 67
###begin p 68
###xml 84 86 84 86 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B14">14</xref>
###xml 273 275 269 271 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B12">12</xref>
###xml 459 461 451 453 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B36">36</xref>
###xml 462 464 454 456 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B37">37</xref>
###xml 683 691 675 683 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F7">Figure 7</xref>
###xml 698 704 690 696 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al.</italic>
###xml 706 708 698 700 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B27">27</xref>
###xml 938 940 930 932 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B27">27</xref>
###xml 1096 1098 1084 1086 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B27">27</xref>
###xml 1248 1256 1232 1240 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F3">Figure 3</xref>
###xml 1345 1347 1329 1331 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B29">29</xref>
###xml 1426 1434 1402 1410 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 1505 1513 1477 1485 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F4">Figure 4</xref>
###xml 115 118 <span type="species:ncbi:10376">EBV</span>
###xml 169 172 <span type="species:ncbi:10376">EBV</span>
###xml 485 488 <span type="species:ncbi:10376">EBV</span>
###xml 596 599 <span type="species:ncbi:10376">EBV</span>
In this study, we describe the activation of miR-155, which is a potential oncomiR (14), by LMP1, a trans-membrane EBV protein considered to be the major oncoprotein of EBV. LMP1 is expressed during viral latency and it activates the signaling pathways NF-kappaB and AP-1 (12). Using miRNA array, it has been reported that LMP1-induced the expression of numerous miRNAs, such as miR-146, whose expression is upregulated by the LMP1-induced NF-kappaB pathway (36,37). Here we show that EBV-infected cells constitutively express high levels of miR-155, and that the exogenous expression of LMP1 in EBV-negative B cells enhances miR-155 expression in a time- and dose-dependent manner (Figure 7). Yin et al. (27) reported that the promoter of the BIC gene encoding miR-155 contains a conserved AP-1 element 40 bases upstream from the transcription start site that is essential for the induction of miR-155 mediated by activation of the BCR (27). They also identified a putative NF-kappaB site at -1150 nt on the BIC promoter whose mutation did not affect miRNA enhancement by activation of the BCR (27). We found an additional NF-kappaB putative binding site at -1697 nt on the BIC promoter. We show that the endogenous promoter is responsive to PMA (Figure 3), a well recognized activator of the canonical inhibitor kinase kinase-dependent (IKK) (29) NF-kappaB pathway. Moreover, both putative NF-kappaB sites were able to bind in vitro the NF-kappaB proteins p50 and p65 in nuclear extract from MC3 cells (Figure 4A).
###end p 68
###begin p 69
###xml 55 57 55 57 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B30">30</xref>
###xml 119 121 115 117 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B31">31</xref>
###xml 520 523 <span type="species:ncbi:10376">EBV</span>
Because LMP1 induces both the canonical IKK-dependent (30) and non-canonical NF-kappaB-induced kinase-dependent (NIK) (31) NF-kappaB pathways, we tested whether p52 (an NF-kappaB protein activated by a non-canonical pathway) was part of the binding complex, but we did not detect it. Accordingly, inhibition of the canonical NF-kappaB pathway by exogenous expression of IkappaBalpha led to reduced expression of miR-155 in MC3 (). This could indicate that the non-canonical pathway is activated only at the beginning of EBV infection when the virus needs to maximize this signaling pathway.
###end p 69
###begin p 70
###xml 51 58 47 54 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 173 181 169 177 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F4">Figure 4</xref>
###xml 444 453 432 441 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F5">Figures 5</xref>
###xml 458 459 446 447 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F6">6</xref>
###xml 520 523 504 507 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">cis</italic>
###xml 836 844 808 816 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F6">Figure 6</xref>
###xml 1023 1031 995 1003 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F6">Figure 6</xref>
###xml 1129 1135 1101 1107 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al.</italic>
###xml 1269 1272 1241 1244 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">cis</italic>
###xml 247 250 <span type="species:ncbi:10376">EBV</span>
Furthermore, both the NF-kappaB sites bound to p65 in vivo as did the RNA pol II on the TATA box of the BIC promoter, in MC3, which indicates ongoing miR-155 transcription (Figure 4B and C) suggesting that the two NF-kappaB sites are active in an EBV-positive background. However, PMA- and LMP1-driven induction was higher with a truncated form of the BIC promoter lacking the distal site (NF-kappaB site 2) than with the full-length promoter (Figures 5 and 6). To shield light on the effectiveness of the two NF-kappaB cis-elements, we performed reporter assays using the full length (pLuc1783) or a truncated form (pLuc1380) of miR-155 promoters either wild-type or mutated in the NF-kappaB site 1, NF-kappaB site 2 or AP-1. Our results indicate that both NF-kappaB sites are pivotal for basal and LMP1-induced expression of miR-155 (Figure 6). Conversely, mutation of the AP-1 site in the pLuc1380 reduced the constitutive expression of the promoter, which in fact was still inducible by LMP1 albeit to a lesser extent (Figure 6). However, mutation of the AP-1 site in the pLuc 1783 abolished the LMP1-induced expression. Yin et al. [unpublished data in (34)] suggested that miR-155 promoter contains one or more CpG islands. The presence of putative CpG as well as cis-elements bound by negative regulatory protein(s) or promoter secondary structures could explain why the truncated form of the promoter, lacking this putative NRE, is inducible at higher extent by both PMA and LMP1.
###end p 70
###begin p 71
###xml 233 241 229 237 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F8">Figure 8</xref>
###xml 293 302 289 298 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F7">Figures 7</xref>
###xml 307 308 303 304 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F8">8</xref>
###xml 54 57 <span type="species:ncbi:10376">EBV</span>
Subsequently, we performed time-course experiments in EBV-negative cells infected with an exogenous LMP1. Our data show that the expression of LMP1 is temporally correlated with the activation of p65 binding on both NF-kappaB sites (Figure 8), recruitment of RNA pol II and miR-155 induction (Figures 7 and 8). All data reported give a clear indication that LMP1 enhances miR-155 expression, mainly, via activation of the canonical NF-kappaB pathway.
###end p 71
###begin p 72
###xml 61 67 61 67 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al.</italic>
###xml 69 71 69 71 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B27">27</xref>
Our results, together with the previous data reported by Yin et al. (27), illustrate the exquisite regulation of this miR by various stimuli, and highlight its importance in B-cell physiology.
###end p 72
###begin p 73
###xml 133 135 133 135 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B35">35</xref>
###xml 708 710 708 710 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B38">38</xref>
###xml 751 753 751 753 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B38">38</xref>
###xml 1095 1097 1095 1097 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B34">34</xref>
###xml 1226 1228 1226 1228 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B14">14</xref>
###xml 1299 1308 1299 1308 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">In silico</italic>
###xml 1359 1361 1359 1361 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B39">39</xref>
###xml 1373 1375 1373 1375 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B40">40</xref>
###xml 1042 1045 <span type="species:ncbi:10376">EBV</span>
###xml 1220 1224 <span type="species:ncbi:10090">mice</span>
###xml 1693 1696 <span type="species:ncbi:10376">EBV</span>
###xml 1711 1714 <span type="species:ncbi:10376">EBV</span>
PU.1 is a downstream effector of miR-155 thanks to the presence of a miR-155 complementary seed sequence in the 3' UTR of PU.1 mRNA (35). In the latter report, B cells lacking miR-155 generated reduced extrafollicular and germinal center responses and did not produce high-affinity IgG1 antibodies. PU.1 is highly expressed in miR-155-deficient B cells and its overexpression in wild-type B cells results in reduced numbers of IgG1-switched cells, which indicates that miR-155 plays a key role in antigen-driven B-cell maturation. PU.1 is a master gene of the Ets transcriptional factor family that promotes cell growth, differentiation and apoptosis thereby playing an important role in hematopoiesis [see (38) for a review]. It is both an oncogene (38) and a tumor suppressor gene that promotes apoptosis. Here we show that LMP1-mediated activation of miR-155 is correlated with diminished levels of the PU.1 protein. Many mRNAs were predicted to be direct targets of miR-155. A recent work reported that miR-155 plays an important role in EBV-regulated gene expression of the infected cells (34). It is thus possible that the phenotypic alterations and the oncogenic potentialities observed in miR-155-overexpressing mice (14) are the result of deregulation of other targets in addition to PU.1. In silico analysis indicated that miR-155 may target SOCS1 (39) and WEE1 (40) (G.G. and M.M., unpublished data), which would better account for its oncogenic role. Probably, a miRNA can have two or more targets or even different targets depending on the cellular context. Studies to elucidate the molecular targets of miR-155 after LMP1 induction, and to determine their reciprocal role during EBV infection and EBV-mediated transformation are underway in our laboratory.
###end p 73
###begin title 74
SUPPLEMENTARY DATA
###end title 74
###begin p 75
 are available at NAR Online.
###end p 75
###begin title 76
FUNDING
###end title 76
###begin p 77
Italian Ministry of Education and Research (MIUR) PRIN 05; Funding for open access charge: Department of Biochemistry and Medical Biotechnologies, University of Naples Federico II, Naples, Italy.
###end p 77
###begin p 78
###xml 0 30 0 30 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Conflict of interest statement</italic>
Conflict of interest statement. None declared.
###end p 78
###begin title 79
Supplementary Material
###end title 79
###begin title 80
[Supplementary Data]
###end title 80
###begin title 81
ACKNOWLEDGEMENTS
###end title 81
###begin p 82
We thank Prof. Ileana Quinto and Prof. Giuseppe Scala for supplying cells, antibodies and other materials and for all the critical suggestions, and Mrs Jean Gilder for the help in editing.
###end p 82
###begin title 83
REFERENCES
###end title 83
###begin article-title 84
###xml 0 18 <span type="species:ncbi:10376">Epstein-Barr virus</span>
Epstein-Barr virus and its replication
###end article-title 84
###begin article-title 85
###xml 0 18 <span type="species:ncbi:10376">Epstein-Barr virus</span>
Epstein-Barr virus and oncogenesis: from latent genes to tumours
###end article-title 85
###begin article-title 86
###xml 18 36 <span type="species:ncbi:10376">Epstein-Barr virus</span>
###xml 90 105 <span type="species:ncbi:10090">transgenic mice</span>
Expression of the Epstein-Barr virus latent membrane protein 1 induces B cell lymphoma in transgenic mice
###end article-title 86
###begin article-title 87
###xml 77 95 <span type="species:ncbi:10376">Epstein-Barr virus</span>
Orientation and patching of the latent infection membrane protein encoded by Epstein-Barr virus
###end article-title 87
###begin article-title 88
###xml 29 47 <span type="species:ncbi:10376">Epstein-Barr virus</span>
Latent membrane protein 1 of Epstein-Barr virus mimics a constitutively active receptor molecule
###end article-title 88
###begin article-title 89
###xml 14 17 <span type="species:ncbi:10376">EBV</span>
Fusion of the EBV latent membrane protein-1 (LMP1) transmembrane domains to the CD40 cytoplasmic domain is similar to LMP1 in constitutive activation of epidermal growth factor receptor expression, nuclear factor-kappa B, and stress-activated protein kinase
###end article-title 89
###begin article-title 90
###xml 4 22 <span type="species:ncbi:10376">Epstein-Barr virus</span>
The Epstein-Barr virus LMP1 amino acid sequence that engages tumor necrosis factor receptor associated factors is critical for primary B lymphocyte growth transformation
###end article-title 90
###begin article-title 91
###xml 4 22 <span type="species:ncbi:10376">Epstein-Barr virus</span>
The Epstein-Barr virus oncogene product latent membrane protein 1 engages the tumor necrosis factor receptor-associated death domain protein to mediate B lymphocyte growth transformation and activate NF-kappaB
###end article-title 91
###begin article-title 92
###xml 4 22 <span type="species:ncbi:10376">Epstein-Barr virus</span>
The Epstein-Barr virus LMP1 cytoplasmic carboxy terminus is essential for B-lymphocyte transformation; fibroblast cocultivation complements a critical function within the terminal 155 residues
###end article-title 92
###begin article-title 93
###xml 0 18 <span type="species:ncbi:10376">Epstein-Barr virus</span>
Epstein-Barr virus-encoded latent membrane protein 1 activates the JNK pathway through its extreme C terminus via a mechanism involving TRADD and TRAF2
###end article-title 93
###begin article-title 94
###xml 62 80 <span type="species:ncbi:10376">Epstein-Barr virus</span>
Activation of the cJun N-terminal kinase (JNK) pathway by the Epstein-Barr virus-encoded latent membrane protein 1 (LMP1)
###end article-title 94
###begin article-title 95
###xml 4 22 <span type="species:ncbi:10376">Epstein-Barr virus</span>
The Epstein-Barr virus transforming protein LMP1 engages signaling proteins for the tumor necrosis factor receptor family
###end article-title 95
###begin article-title 96
###xml 39 59 <span type="species:ncbi:11864">avian leukosis virus</span>
Multiple proto-oncogene activations in avian leukosis virus-induced lymphomas, evidence for stage-specific events
###end article-title 96
###begin article-title 97
###xml 88 103 <span type="species:ncbi:10090">transgenic mice</span>
Pre-B cell proliferation and lymphoblastic leukemia/high-grade lymphoma in E(mu)-miR155 transgenic mice
###end article-title 97
###begin article-title 98
BIC and miR-155 are highly expressed in Hodgkin, primary mediastinal and diffuse large B cell lymphomas
###end article-title 98
###begin article-title 99
High expression of B-cell receptor inducible gene BIC in all subtypes of Hodgkin lymphoma
###end article-title 99
###begin article-title 100
###xml 35 40 <span type="species:ncbi:9606">human</span>
A microRNA expression signature of human solid tumors defines cancer gene targets
###end article-title 100
###begin article-title 101
###xml 60 80 <span type="species:ncbi:11864">avian leukosis virus</span>
Avian bic, a gene isolated from a common retroviral site in avian leukosis virus-induced lymphomas that encodes a noncoding RNA, cooperates with c-myc in lymphomagenesis and erythroleukemogenesis
###end article-title 101
###begin article-title 102
Unique microRNA molecular profiles in lung cancer diagnosis and prognosis
###end article-title 102
###begin article-title 103
Regulation of the germinal center response by microRNA-155
###end article-title 103
###begin article-title 104
Requirement of bic/microRNA-155 for normal immune function
###end article-title 104
###begin article-title 105
MicroRNA-155 is induced during the macrophage inflammatory response
###end article-title 105
###begin article-title 106
###xml 67 83 <span type="species:ncbi:10665">bacteriophage T4</span>
Cleavage of structural proteins during the assembly of the head of bacteriophage T4
###end article-title 106
###begin article-title 107
###xml 85 88 <span type="species:ncbi:10376">EBV</span>
###xml 98 103 <span type="species:ncbi:9606">human</span>
Subtractive hybridization identifies novel differentially expressed ncRNA species in EBV-infected human B cells
###end article-title 107
###begin article-title 108
###xml 0 18 <span type="species:ncbi:10376">Epstein-Barr virus</span>
###xml 80 85 <span type="species:ncbi:9606">human</span>
Epstein-Barr virus nuclear antigen 2 transactivates the long terminal repeat of human immuno-deficiency virus type 1
###end article-title 108
###begin article-title 109
###xml 49 54 <span type="species:ncbi:9606">human</span>
Expression of an exogenous interleukin 6 gene in human Epstein Barr virus B cells confers growth advantage and in vivo tumorigenicity
###end article-title 109
###begin article-title 110
B-cell Receptor Activation Induces BIC/miR-155 Expression through a Conserved AP-1 Element
###end article-title 110
###begin article-title 111
###xml 39 44 <span type="species:ncbi:9606">human</span>
Identification and characterization of human BIC, a gene on chromosome 21 that encodes a noncoding RNA
###end article-title 111
###begin article-title 112
Activation of NF-kappaB mediates the PMA-induced differentiation of K562 cells
###end article-title 112
###begin article-title 113
###xml 0 18 <span type="species:ncbi:10376">Epstein-Barr virus</span>
Epstein-Barr virus latent infection membrane protein 1 TRAF-binding site induces NIK/IKK alpha-dependent noncanonical NF-kappaB activation
###end article-title 113
###begin article-title 114
###xml 0 18 <span type="species:ncbi:10376">Epstein-Barr virus</span>
Epstein-Barr virus-encoded latent infection membrane protein 1 regulates the processing of p100 NF-kappaB2 to p52 via an IKKgamma/NEMO-independent signalling pathway
###end article-title 114
###begin article-title 115
Control of I kappa B-alpha proteolysis by site-specific, signal-induced phosphorylation
###end article-title 115
###begin article-title 116
MicroRNA genes are transcribed by RNA polymerase II
###end article-title 116
###begin article-title 117
###xml 19 37 <span type="species:ncbi:10376">Epstein-Barr virus</span>
###xml 66 84 <span type="species:ncbi:10376">Epstein-Barr virus</span>
MicroRNA-155 is an Epstein-Barr virus-induced gene that modulates Epstein-Barr virus-regulated gene expression pathways
###end article-title 117
###begin article-title 118
microRNA-155 regulates the generation of immunoglobulin class-switched plasma cells
###end article-title 118
###begin article-title 119
###xml 0 18 <span type="species:ncbi:10376">Epstein-Barr virus</span>
Epstein-Barr virus latent membrane protein 1 induces cellular microRNA miR-146a, a modulator of lymphocyte signaling pathways
###end article-title 119
###begin article-title 120
###xml 0 18 <span type="species:ncbi:10376">Epstein-Barr virus</span>
Epstein-Barr virus-encoded latent membrane protein 1 (LMP1) induces the expression of the cellular microRNA miR-146a
###end article-title 120
###begin article-title 121
The role of Ets family transcription factor PU.1 in hematopoietic cell differentiation, proliferation and apoptosis
###end article-title 121
###begin article-title 122
The negative regulatory roles of suppressor of cytokine signaling proteins in myeloid signaling pathways
###end article-title 122
###begin article-title 123
Wee1-dependent mechanisms required for coordination of cell growth and cell division
###end article-title 123

